Personalizing rabbit anti-thymocyte globulin therapy for prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation: is there an optimal dose?

被引：18

作者：

Shichijo, Takafumi ^{[1
,2
]}

Fuji, Shigeo ^{[3
]}

Nagler, Arnon ^{[4
]}

Bazarbachi, Abdulhamid ^{[5
,6
,7
]}

Mohty, Mohamad ^{[5
,6
,7
]}

Savani, Bipin N. ^{[7
,8
]}

机构：

[1] Kumamoto Univ, Fac Life Sci, Dept Hematol Rheumatol & Infect Dis, Kumamoto, Japan

[2] Kyoto Univ, Inst Frontier Life & Med Sci, Lab Virus Control, Kyoto, Japan

[3] Osaka Int Canc Inst, Dept Hematol, Osaka, Japan

[4] Tel Aviv Univ, Chaim Sheba Med Ctr, Tel Hashomer, Israel

[5] St Antoine Hosp, INSERM, UMR 938, Serv Hematol Clin & Therapie Cellulaire, Paris, France

[6] St Antoine Hosp, INSERM, UMR 938, EBMT Paris Study Off, Paris, France

[7] Sorbonne Univ, Paris, France

[8] Vanderbilt Univ, Med Ctr, Div Hematol & Oncol, Nashville, TN USA

来源：

BONE MARROW TRANSPLANTATION | 2020年 / 55卷 / 03期

关键词：

LEUKEMIA WORKING PARTY; T-LYMPHOCYTE GLOBULIN; BONE-MARROW-TRANSPLANTATION; MATCHED UNRELATED DONORS; ACUTE MYELOID-LEUKEMIA; INTENSITY CONDITIONING REGIMEN; CONSENSUS DEVELOPMENT PROJECT; SEVERE APLASTIC-ANEMIA; BLOOD STEM-CELLS; TERM-FOLLOW-UP;

D O I：

10.1038/s41409-019-0643-9

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

The efficacy of anti-thymocyte globulin (ATG) as prophylaxis for graft-versus-host disease (GVHD) has been investigated by many clinical studies over the past decade, including some randomized controlled trials. Intriguingly, although ATG is commonly used as prophylaxis for GVHD, there is still controversy about the optimal dose of ATG for prophylaxis of GVHD after allogeneic hematopoietic cell transplantation (allo-HCT). Indeed, the dose and formulation of ATG, as well as the degree of clinical benefit, has varied among studies, which makes it difficult to fully determine the clinical benefit of ATG. The aim of this review is to summarize the information regarding the optimal ATG dose of each formulation according to stem cell source, and to discuss how best to determine the personalized optimal dose of ATG in each allo-HCT recipient.

引用

页码：505 / 522

页数：18

共 50 条

[1] Personalizing rabbit anti-thymocyte globulin therapy for prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation: is there an optimal dose?
Takafumi Shichijo
Shigeo Fuji
Arnon Nagler
Abdulhamid Bazarbachi
Mohamad Mohty
Bipin N. Savani
[J]. Bone Marrow Transplantation, 2020, 55 : 505 - 522
[2] Low dose rabbit anti-thymocyte globulin for graft versus host disease prophylaxis after unrelated hematopoietic stem cell transplantation in pediatric patients
Atay, Didem
Erbey, Fatih
Akcay, Arzu
Akmuradova, Aygozel
Seferkolli, Florenc
Ozturk, Gulyuz
[J]. BONE MARROW TRANSPLANTATION, 2018, 53 : 431 - 432
[3] Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience
Sara Butera
Marco Cerrano
Lucia Brunello
Chiara Maria Dellacasa
Danilo Giuseppe Faraci
Sara Vassallo
Nicola Mordini
Roberto Sorasio
Francesco Zallio
Alessandro Busca
Benedetto Bruno
Luisa Giaccone
[J]. Annals of Hematology, 2021, 100 : 1837 - 1847
[4] Low-dose anti-thymocyte globulin reduce severe acute and chronic graft-versus-host disease after allogeneic stem cell transplantation
Osamu Imataki
Kensuke Matsumoto
Makiko Uemura
[J]. Journal of Cancer Research and Clinical Oncology, 2017, 143 : 709 - 715
[5] Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience
Butera, Sara
Cerrano, Marco
Brunello, Lucia
Dellacasa, Chiara Maria
Faraci, Danilo Giuseppe
Vassallo, Sara
Mordini, Nicola
Sorasio, Roberto
Zallio, Francesco
Busca, Alessandro
Bruno, Benedetto
Giaccone, Luisa
[J]. ANNALS OF HEMATOLOGY, 2021, 100 (07) : 1837 - 1847
[6] Low-dose anti-thymocyte globulin reduce severe acute and chronic graft-versus-host disease after allogeneic stem cell transplantation
Imataki, Osamu
Matsumoto, Kensuke
Uemura, Makiko
[J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2017, 143 (04) : 709 - 715
[7] Outcomes with low dose anti-thymocyte globulin based graft versus host disease prophylaxis after mismatched unrelated donor allogeneic hematopoietic cell transplantation
Chalchal, Hafsah
Dhir, Vinita
Masurekar, Ashish
Atkins, Harold
Bredeson, Christopher
Kennah, Michael
Kekre, Natasha
Allan, David
Nampoothiri, Ram Vasudevan
[J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2024,
[8] Proinflammatory Cytokine Release and Infusional Side-Effects after Anti-Thymocyte Globulin Serotherapy for Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Cell Transplantation
Khanolkar, Rutvij A.
Dookie, Stephanie
Li, Na
Khan, Faisal
Storek, Jan
[J]. BLOOD, 2023, 142
[9] Anti-thymocyte globulin (ATG) for steroid-resistant acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: A costly therapy with limited benefits.
Khoury, H
Kashyap, A
Brewster, C
Gilfillan, KR
Adkins, D
Brown, R
Miller, G
Vij, R
Westervelt, P
Goodnough, LT
Forman, S
DiPersio, JF
[J]. BLOOD, 1999, 94 (10) : 668A - 668A
[10] Anti-thymocyte globulin to prevent graft versus host disease after HLA matched related allogeneic hematopoietic cell transplantation in acute leukemia patients
Yafour, N.
Serradj, F.
Osmani, S.
Bouamama, F.
Brahimi, M.
Chekkal, M.
Bouhafs, K.
Baki, A.
Arabi, A.
Bouhass, R.
Bekadja, M. A.
[J]. BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 216 - 217

← 1 2 3 4 5 →